B-Organism_substance	0	5	Grape	Grape	NN	B-NP
I-Organism_substance	6	10	seed	seed	NN	I-NP
I-Organism_substance	11	18	extract	extract	NN	I-NP
O	19	27	inhibits	inhibit	VBZ	B-VP
O	28	40	angiogenesis	angiogenesis	NN	B-NP
O	41	44	via	via	IN	B-PP
O	45	56	suppression	suppression	NN	B-NP
O	57	59	of	of	IN	B-PP
O	60	63	the	the	DT	B-NP
O	64	72	vascular	vascular	JJ	I-NP
O	73	84	endothelial	endothelial	JJ	I-NP
O	85	91	growth	growth	NN	I-NP
O	92	98	factor	factor	NN	I-NP
O	99	107	receptor	receptor	NN	I-NP
O	108	117	signaling	signaling	NN	I-NP
O	118	125	pathway	pathway	NN	I-NP
O	125	126	.	.	.	O

O	127	135	Blockade	Blockade	NN	B-NP
O	136	138	of	of	IN	B-PP
O	139	151	angiogenesis	angiogenesis	NN	B-NP
O	152	154	is	be	VBZ	B-VP
O	155	157	an	an	DT	B-NP
O	158	167	important	important	JJ	I-NP
O	168	176	approach	approach	NN	I-NP
O	177	180	for	for	IN	B-PP
B-Cancer	181	187	cancer	cancer	NN	B-NP
O	188	197	treatment	treatment	NN	I-NP
O	198	201	and	and	CC	I-NP
O	202	212	prevention	prevention	NN	I-NP
O	212	213	.	.	.	O

O	214	222	Vascular	Vascular	JJ	B-NP
O	223	234	endothelial	endothelial	JJ	I-NP
O	235	241	growth	growth	NN	I-NP
O	242	248	factor	factor	NN	I-NP
O	249	250	(	(	(	O
O	250	254	VEGF	VEGF	NN	B-NP
O	254	255	)	)	)	O
O	256	258	is	be	VBZ	B-VP
O	259	262	one	one	CD	B-NP
O	263	265	of	of	IN	B-PP
O	266	269	the	the	DT	B-NP
O	270	274	most	most	RBS	I-NP
O	275	283	critical	critical	JJ	I-NP
O	284	291	factors	factor	NNS	I-NP
O	292	296	that	that	WDT	B-NP
O	297	303	induce	induce	VBP	B-VP
O	304	316	angiogenesis	angiogenesis	NN	B-NP
O	317	320	and	and	CC	O
O	321	324	has	have	VBZ	B-VP
O	325	329	thus	thus	RB	I-VP
O	330	336	become	become	VBN	I-VP
O	337	339	an	an	DT	B-NP
O	340	350	attractive	attractive	JJ	I-NP
O	351	357	target	target	NN	I-NP
O	358	361	for	for	IN	B-PP
O	362	378	antiangiogenesis	antiangiogenesis	NN	B-NP
O	379	388	treatment	treatment	NN	I-NP
O	388	389	.	.	.	O

O	390	397	However	However	RB	B-ADVP
O	397	398	,	,	,	O
O	399	403	most	most	RBS	B-NP
O	404	411	current	current	JJ	I-NP
O	412	416	anti	anti	AFX	I-NP
O	416	417	-	-	HYPH	I-NP
O	417	421	VEGF	VEGF	NN	B-NP
O	422	428	agents	agent	NNS	I-NP
O	429	434	often	often	RB	B-ADVP
O	435	440	cause	cause	VBP	B-VP
O	441	445	some	some	DT	B-NP
O	446	450	side	side	NN	I-NP
O	451	458	effects	effect	NNS	I-NP
O	459	463	when	when	WRB	B-ADVP
O	464	469	given	give	VBN	B-VP
O	470	481	chronically	chronically	RB	B-ADVP
O	481	482	.	.	.	O

O	483	497	Identification	Identification	NN	B-NP
O	498	500	of	of	IN	B-PP
O	501	510	naturally	naturally	RB	B-VP
O	511	520	occurring	occur	VBG	I-VP
O	521	525	VEGF	VEGF	NN	B-NP
O	526	536	inhibitors	inhibitor	NNS	I-NP
O	537	544	derived	derive	VBN	B-VP
O	545	549	from	from	IN	B-PP
O	550	554	diet	diet	NN	B-NP
O	555	560	would	would	MD	B-VP
O	561	563	be	be	VB	I-VP
O	564	567	one	one	CD	B-NP
O	568	579	alternative	alternative	JJ	I-NP
O	580	588	approach	approach	NN	I-NP
O	589	593	with	with	IN	B-PP
O	594	596	an	an	DT	B-NP
O	597	606	advantage	advantage	NN	I-NP
O	607	609	of	of	IN	B-PP
O	610	615	known	know	VBN	B-NP
O	616	622	safety	safety	NN	I-NP
O	622	623	.	.	.	O

B-Organism_substance	624	629	Grape	Grape	NN	B-NP
I-Organism_substance	630	634	seed	seed	NN	I-NP
I-Organism_substance	635	642	extract	extract	NN	I-NP
O	643	644	(	(	(	O
B-Organism_substance	644	647	GSE	GSE	NN	B-NP
O	647	648	)	)	)	O
O	648	649	,	,	,	O
O	650	651	a	a	DT	B-NP
O	652	658	widely	widely	RB	I-NP
O	659	663	used	use	VBN	I-NP
O	664	671	dietary	dietary	JJ	I-NP
O	672	682	supplement	supplement	NN	I-NP
O	682	683	,	,	,	O
O	684	686	is	be	VBZ	B-VP
O	687	692	known	know	VBN	I-VP
O	693	695	to	to	TO	I-VP
O	696	700	have	have	VB	I-VP
B-Cancer	701	710	antitumor	antitumor	JJ	B-NP
O	711	719	activity	activity	NN	I-NP
O	719	720	.	.	.	O

O	721	723	In	In	IN	B-PP
O	724	728	this	this	DT	B-NP
O	729	734	study	study	NN	I-NP
O	734	735	,	,	,	O
O	736	738	we	we	PRP	B-NP
O	739	743	have	have	VBP	B-VP
O	744	752	explored	explore	VBN	I-VP
O	753	756	the	the	DT	B-NP
O	757	765	activity	activity	NN	I-NP
O	766	768	of	of	IN	B-PP
B-Organism_substance	769	772	GSE	GSE	NN	B-NP
O	773	775	on	on	IN	B-PP
O	776	780	VEGF	VEGF	NN	B-NP
O	781	789	receptor	receptor	NN	I-NP
O	790	793	and	and	CC	I-NP
O	794	806	angiogenesis	angiogenesis	NN	I-NP
O	806	807	.	.	.	O

O	808	810	We	We	PRP	B-NP
O	811	816	found	find	VBD	B-VP
O	817	821	that	that	IN	B-SBAR
B-Organism_substance	822	825	GSE	GSE	NN	B-NP
O	826	831	could	could	MD	B-VP
O	832	840	directly	directly	RB	I-VP
O	841	848	inhibit	inhibit	VB	I-VP
O	849	852	the	the	DT	B-NP
O	853	859	kinase	kinase	NN	I-NP
O	860	868	activity	activity	NN	I-NP
O	869	871	of	of	IN	B-PP
O	872	880	purified	purify	VBN	B-NP
O	881	885	VEGF	VEGF	NN	I-NP
O	886	894	receptor	receptor	NN	I-NP
O	895	896	2	2	CD	I-NP
O	896	897	,	,	,	O
O	898	899	a	a	DT	B-NP
O	900	905	novel	novel	JJ	I-NP
O	906	914	activity	activity	NN	I-NP
O	915	917	of	of	IN	B-PP
B-Organism_substance	918	921	GSE	GSE	NN	B-NP
O	922	926	that	that	WDT	B-NP
O	927	930	has	have	VBZ	B-VP
O	931	934	not	not	RB	I-VP
O	935	939	been	be	VBN	I-VP
O	940	953	characterized	characterize	VBN	I-VP
O	953	954	.	.	.	O

B-Organism_substance	955	958	GSE	GSE	NN	B-NP
O	959	964	could	could	MD	B-VP
O	965	969	also	also	RB	I-VP
O	970	977	inhibit	inhibit	VB	I-VP
O	978	981	the	the	DT	B-NP
O	982	986	VEGF	VEGF	NN	I-NP
O	987	995	receptor	receptor	NN	I-NP
O	995	996	/	/	SYM	B-NP
O	996	1003	mitogen	mitogen	NN	I-NP
O	1003	1004	-	-	HYPH	O
O	1004	1013	activated	activate	VBN	B-NP
O	1014	1021	protein	protein	NN	I-NP
O	1022	1028	kinase	kinase	NN	I-NP
O	1028	1029	-	-	HYPH	B-VP
O	1029	1037	mediated	mediate	VBN	B-NP
O	1038	1047	signaling	signaling	NN	I-NP
O	1048	1055	pathway	pathway	NN	I-NP
O	1056	1058	in	in	IN	B-PP
B-Cell	1059	1070	endothelial	endothelial	JJ	B-NP
I-Cell	1071	1076	cells	cell	NNS	I-NP
O	1076	1077	.	.	.	O

O	1078	1080	As	As	IN	B-PP
O	1081	1082	a	a	DT	B-NP
O	1083	1089	result	result	NN	I-NP
O	1089	1090	,	,	,	O
B-Organism_substance	1091	1094	GSE	GSE	NN	B-NP
O	1095	1100	could	could	MD	B-VP
O	1101	1108	inhibit	inhibit	VB	I-VP
O	1109	1113	VEGF	VEGF	NN	B-NP
O	1113	1114	-	-	HYPH	O
O	1114	1121	induced	induce	VBN	B-NP
B-Cell	1122	1133	endothelial	endothelial	JJ	I-NP
I-Cell	1134	1138	cell	cell	NN	I-NP
O	1139	1152	proliferation	proliferation	NN	I-NP
O	1153	1156	and	and	CC	I-NP
O	1157	1166	migration	migration	NN	I-NP
O	1167	1169	as	as	RB	B-CONJP
O	1170	1174	well	well	RB	I-CONJP
O	1175	1177	as	as	IN	I-CONJP
B-Tissue	1178	1184	sprout	sprout	NN	B-NP
O	1185	1194	formation	formation	NN	I-NP
O	1195	1199	from	from	IN	B-PP
B-Multi-tissue_structure	1200	1205	aorta	aorta	NN	B-NP
I-Multi-tissue_structure	1206	1210	ring	ring	NN	I-NP
O	1210	1211	.	.	.	O

O	1212	1214	In	In	FW	B-NP
O	1215	1219	vivo	vivo	FW	I-NP
O	1220	1225	assay	assay	NN	I-NP
O	1226	1233	further	further	RB	B-ADVP
O	1234	1240	showed	show	VBD	B-VP
O	1241	1245	that	that	IN	B-SBAR
B-Organism_substance	1246	1249	GSE	GSE	NN	B-NP
O	1250	1255	could	could	MD	B-VP
O	1256	1263	inhibit	inhibit	VB	I-VP
B-Cancer	1264	1269	tumor	tumor	NN	B-NP
O	1270	1276	growth	growth	NN	I-NP
O	1277	1280	and	and	CC	O
B-Cancer	1281	1286	tumor	tumor	NN	B-NP
O	1287	1299	angiogenesis	angiogenesis	NN	I-NP
O	1300	1302	of	of	IN	B-PP
B-Cell	1303	1306	MDA	MDA	NN	B-NP
I-Cell	1306	1307	-	-	HYPH	B-NP
I-Cell	1307	1309	MB	MB	NN	I-NP
I-Cell	1309	1310	-	-	HYPH	I-NP
I-Cell	1310	1313	231	231	CD	I-NP
I-Cell	1314	1320	breast	breast	NN	I-NP
I-Cell	1321	1327	cancer	cancer	NN	I-NP
I-Cell	1328	1333	cells	cell	NNS	I-NP
O	1334	1336	in	in	IN	B-PP
O	1337	1341	mice	mouse	NNS	B-NP
O	1341	1342	.	.	.	O

O	1343	1353	Consistent	Consistent	JJ	B-ADJP
O	1354	1358	with	with	IN	B-PP
O	1359	1362	the	the	DT	B-NP
O	1363	1365	in	in	FW	I-NP
O	1366	1371	vitro	vitro	FW	I-NP
O	1372	1376	data	datum	NNS	I-NP
O	1376	1377	,	,	,	O
B-Organism_substance	1378	1381	GSE	GSE	NN	B-NP
O	1382	1391	treatment	treatment	NN	I-NP
O	1392	1394	of	of	IN	B-PP
B-Cancer	1395	1400	tumor	tumor	NN	B-NP
O	1400	1401	-	-	HYPH	O
O	1401	1408	bearing	bear	VBG	B-NP
O	1409	1413	mice	mouse	NNS	I-NP
O	1414	1417	led	lead	VBD	B-VP
O	1418	1420	to	to	TO	B-PP
O	1421	1432	concomitant	concomitant	JJ	B-NP
O	1433	1442	reduction	reduction	NN	I-NP
O	1443	1445	of	of	IN	B-PP
B-Multi-tissue_structure	1446	1451	blood	blood	NN	B-NP
I-Multi-tissue_structure	1452	1458	vessel	vessel	NN	I-NP
O	1459	1466	density	density	NN	I-NP
O	1467	1470	and	and	CC	I-NP
O	1471	1486	phosphorylation	phosphorylation	NN	I-NP
O	1487	1489	of	of	IN	B-PP
O	1490	1497	mitogen	mitogen	NN	B-NP
O	1497	1498	-	-	HYPH	B-NP
O	1498	1507	activated	activate	VBN	I-NP
O	1508	1515	protein	protein	NN	I-NP
O	1516	1522	kinase	kinase	NN	I-NP
O	1522	1523	.	.	.	O

O	1524	1533	Depletion	Depletion	NN	B-NP
O	1534	1536	of	of	IN	B-PP
O	1537	1547	polyphenol	polyphenol	NN	B-NP
O	1548	1552	with	with	IN	B-PP
O	1553	1573	polyvinylpyrrolidone	polyvinylpyrrolidone	NN	B-NP
O	1574	1583	abolished	abolish	VBD	B-VP
O	1584	1587	the	the	DT	B-NP
O	1588	1602	antiangiogenic	antiangiogenic	JJ	I-NP
O	1603	1611	activity	activity	NN	I-NP
O	1612	1614	of	of	IN	B-PP
B-Organism_substance	1615	1618	GSE	GSE	NN	B-NP
O	1618	1619	,	,	,	O
O	1620	1630	suggesting	suggest	VBG	B-VP
O	1631	1632	a	a	DT	B-NP
O	1633	1638	water	water	NN	I-NP
O	1638	1639	-	-	HYPH	B-NP
O	1639	1646	soluble	soluble	JJ	I-NP
O	1647	1655	fraction	fraction	NN	I-NP
O	1656	1658	of	of	IN	B-PP
O	1659	1669	polyphenol	polyphenol	NN	B-NP
O	1670	1672	in	in	IN	B-PP
B-Organism_substance	1673	1676	GSE	GSE	NN	B-NP
O	1677	1679	is	be	VBZ	B-VP
O	1680	1691	responsible	responsible	JJ	B-ADJP
O	1692	1695	for	for	IN	B-PP
O	1696	1699	the	the	DT	B-NP
O	1700	1714	antiangiogenic	antiangiogenic	JJ	I-NP
O	1715	1723	activity	activity	NN	I-NP
O	1723	1724	.	.	.	O

O	1725	1730	Taken	Take	VBN	B-VP
O	1731	1739	together	together	RB	B-ADVP
O	1739	1740	,	,	,	O
O	1741	1745	this	this	DT	B-NP
O	1746	1751	study	study	NN	I-NP
O	1752	1761	indicates	indicate	VBZ	B-VP
O	1762	1766	that	that	IN	B-SBAR
B-Organism_substance	1767	1770	GSE	GSE	NN	B-NP
O	1771	1773	is	be	VBZ	B-VP
O	1774	1775	a	a	DT	B-NP
O	1776	1780	well	well	RB	I-NP
O	1780	1781	-	-	HYPH	I-NP
O	1781	1790	tolerated	tolerate	VBN	I-NP
O	1791	1794	and	and	CC	I-NP
O	1795	1806	inexpensive	inexpensive	JJ	I-NP
O	1807	1814	natural	natural	JJ	I-NP
O	1815	1819	VEGF	VEGF	NN	I-NP
O	1820	1829	inhibitor	inhibitor	NN	I-NP
O	1830	1833	and	and	CC	O
O	1834	1839	could	could	MD	B-VP
O	1840	1851	potentially	potentially	RB	I-VP
O	1852	1854	be	be	VB	I-VP
O	1855	1861	useful	useful	JJ	B-ADJP
O	1862	1864	in	in	IN	B-PP
B-Cancer	1865	1871	cancer	cancer	NN	B-NP
O	1872	1882	prevention	prevention	NN	I-NP
O	1883	1885	or	or	CC	I-NP
O	1886	1895	treatment	treatment	NN	I-NP
O	1895	1896	.	.	.	O

